BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16000857)

  • 1. A convenient and sensitive fluorescence resonance energy transfer assay for RNase L and 2',5' oligoadenylates.
    Thakur CS; Xu Z; Wang Z; Novince Z; Silverman RH
    Methods Mol Med; 2005; 116():103-13. PubMed ID: 16000857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2-5A system in viral infection and apoptosis.
    Castelli J; Wood KA; Youle RJ
    Biomed Pharmacother; 1998; 52(9):386-90. PubMed ID: 9856285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNase L plays a role in the antiviral response to West Nile virus.
    Scherbik SV; Paranjape JM; Stockman BM; Silverman RH; Brinton MA
    J Virol; 2006 Mar; 80(6):2987-99. PubMed ID: 16501108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction of 8-methyladenosine into 2', 5'-oligoadenylate (2-5A) 2'-terminus induces dramatic shift in binding site of RNase L.
    Nagaoka K; Kito S; Kitamura Y; Ueno Y; Kitade Y
    Nucleic Acids Symp Ser (Oxf); 2009; (53):123-4. PubMed ID: 19749291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L.
    Malathi K; Paranjape JM; Bulanova E; Shim M; Guenther-Johnson JM; Faber PW; Eling TE; Williams BR; Silverman RH
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14533-8. PubMed ID: 16203993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [RNase L, a crucial mediator of innate immunity and other cell functions].
    Bisbal C; Salehzada T
    Med Sci (Paris); 2008 Oct; 24(10):859-64. PubMed ID: 18950583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High yield synthesis, purification and characterisation of the RNase L activators 5'-triphosphate 2'-5'-oligoadenylates.
    Morin B; Rabah N; Boretto-Soler J; Tolou H; Alvarez K; Canard B
    Antiviral Res; 2010 Sep; 87(3):345-52. PubMed ID: 20547186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNase L Antiviral Activity Is Not a Critical Component of the Oas1b-Mediated Flavivirus Resistance Phenotype.
    Madden JC; Cui D; Brinton MA
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phenolic small molecule inhibitor of RNase L prevents cell death from ADAR1 deficiency.
    Daou S; Talukdar M; Tang J; Dong B; Banerjee S; Li Y; Duffy NM; Ogunjimi AA; Gaughan C; Jha BK; Gish G; Tavernier N; Mao D; Weiss SR; Huang H; Silverman RH; Sicheri F
    Proc Natl Acad Sci U S A; 2020 Oct; 117(40):24802-24812. PubMed ID: 32958664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2'-5'-oligoadenylate synthetase 3 enzyme potently synthesizes the 2'-5'-oligoadenylates required for RNase L activation.
    Ibsen MS; Gad HH; Thavachelvam K; Boesen T; Desprès P; Hartmann R
    J Virol; 2014 Dec; 88(24):14222-31. PubMed ID: 25275129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Many Faces of Oligoadenylate Synthetases.
    Sarkar SN; Harioudh MK; Shao L; Perez J; Ghosh A
    J Interferon Cytokine Res; 2023 Nov; 43(11):487-494. PubMed ID: 37751211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity and Mechanism of Coronavirus, Rotavirus, and Mammalian Two-Histidine Phosphoesterases That Antagonize Antiviral Innate Immunity.
    Asthana A; Gaughan C; Dong B; Weiss SR; Silverman RH
    mBio; 2021 Aug; 12(4):e0178121. PubMed ID: 34372695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assays for the interferon-induced enzyme 2',5' oligoadenylate synthetases.
    Sarkar SN; Pandey M; Sen GC
    Methods Mol Med; 2005; 116():81-101. PubMed ID: 16000856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells.
    Molinaro RJ; Jha BK; Malathi K; Varambally S; Chinnaiyan AM; Silverman RH
    Nucleic Acids Res; 2006; 34(22):6684-95. PubMed ID: 17145707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-phase synthesis of 5'-triphosphate 2'-5'-oligoadenylates analogs with 3'-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.
    Thillier Y; Stevens SK; Moy C; Taylor J; Vasseur JJ; Beigelman L; Debart F
    Bioorg Med Chem; 2013 Sep; 21(17):5461-9. PubMed ID: 23810677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5'-O-dephosphorylated 2',5'-oligoadenylate (2-5A) with 8-methyladenosine at the 2'-terminus activates human RNase L.
    Nagaoka K; Kitamura Y; Ueno Y; Kitade Y
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1186-8. PubMed ID: 20022497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L.
    Townsend HL; Jha BK; Han JQ; Maluf NK; Silverman RH; Barton DJ
    RNA; 2008 Jun; 14(6):1026-36. PubMed ID: 18426919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotavirus Controls Activation of the 2'-5'-Oligoadenylate Synthetase/RNase L Pathway Using at Least Two Distinct Mechanisms.
    Sánchez-Tacuba L; Rojas M; Arias CF; López S
    J Virol; 2015 Dec; 89(23):12145-53. PubMed ID: 26401041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.
    Player MR; Torrence PF
    Pharmacol Ther; 1998 May; 78(2):55-113. PubMed ID: 9623881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dom34 mediates targeting of exogenous RNA in the antiviral OAS/RNase L pathway.
    Nogimori T; Nishiura K; Kawashima S; Nagai T; Oishi Y; Hosoda N; Imataka H; Kitamura Y; Kitade Y; Hoshino SI
    Nucleic Acids Res; 2019 Jan; 47(1):432-449. PubMed ID: 30395302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.